CCR

CCR Related Products (102):

By Effects:	Ligand (1) Controls (2) Inhibitors (48) Agonists (2) Antagonists (39) Modulator (1)

Cat. No.	Product Name	Effect	Purity

HY-B0673

Pirfenidone	Inhibitor	99.99%
Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.

HY-B0498

Bindarit	Inhibitor	99.53%
Bindarit (AF2838) is a selective inhibitor of the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8, and no effect on other CC and CXC chemokines such as MIP-1α/CCL3, MIP-1β/CCL4, MIP-3/CCL23. Bindarit also has anti-inflammatory activity.

HY-P3719

MOG(35-55) amide, mouse, rat		99.50%
MOG peptide (35-55) is a fragment 35-55 of myelin oligodendrocyte glycoprotein (MOG) immunogenic peptide. MOG peptide (35-55) is specific to expanded CD4⁺ T cells, and induces experimental autoimmune encephalomyelitis (EAE) in animal model.

HY-P99188

Carlumab	Inhibitor
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) antibody with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer.

HY-N2609

7,4'-Dihydroxyflavone	Inhibitor	99.68%
7,4'-Dihydroxyflavone (7,4'-DHF) is a flavonoid, which can be isolated from Glycyrrhiza uralensis. 7,4'-Dihydroxyflavone is eotaxin/CCL11 inhibitor and CBR1 inhibitor (IC₅₀=0.28 μM). 7,4'-Dihydroxyflavone has the ability to consistently suppress eotaxin production and prevent dexamethasone (Dex)‐paradoxical adverse effects on eotaxin production. 7,4'-Dihydroxyflavone (7,4'-DHF) inhibits MUC5AC gene expression, mucus production and secretion via regulation of NF-κB, STAT6 and HDAC2.7,4'-Dihydroxyflavone (7,4'-DHF) decreases phorbol 12-myristate 13-acetate (PMA) stimulated NCI-H292 human airway epithelial cell MUC5AC gene expression and mucus production with IC₅₀ value of 1.4 µM.

HY-P991224

CAP-100	Inhibitor
CAP-100 is a monoclonal antibody that targets CCR7. CAP-100 neutralizes the ligand-binding site and signaling of CCR7. CAP-100 strongly inhibits CCR7-induced migration, extravasation, homing, and survival in chronic lymphocytic leukemia (CLL) samples. CAP-100 triggers potent tumor cell killing, mediated by host immune mechanism. CAP-100 shows a favorable toxicity profile on relevant hematopoietic subsets. CAP-100 is involved in research on anti-tumor and disease such as CLL.

HY-173491

CXCR2/CCR7 antagonist-1	Antagonist
CXCR2/CCR7 antagonist-1 (compound 6) is a potent CXCR2 and CCR7 dual antagonist with IC₅₀s of 0.0046 and 0.0014 μM, respectively. CXCR2/CCR7 antagonist-1 can be used in the study of cancer metastasis and autoimmune diseases.

HY-P991168

Velaprumig	Inhibitor
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities.

HY-116835

BI-6901	Antagonist	99.94%
BI 6901 is a potent, selective CCR10 antagonist (pIC₅₀=9.0). BI 6901 shows high selectivity over other GPCRs, including a number of other chemokine receptors. BI 6901 is efficacious in the murine DNFB model of contact hypersensitivity and can be used for inflammation research.

HY-P990297

Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5)	Inhibitor
Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) is an anti-mouse/rat/human CCL2/MCP-1 IgG monoclonal antibody. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reverse the immunosuppressive microenvironment by blocking the CCL2 signaling pathway. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can reduce the secretion of IFN-γ and the infiltration of macrophages. CCL2/MCP-1 Antibody (2H5) can reduce the amount of HIV virus by increasing the proportion of T cells. Anti-Mouse/Rat/Human CCL2/MCP-1 Antibody (2H5) can be used for researches on inflammation conditions, virus infection and cancer such as inflammatory bowel disease (IBD), hepatocellular carcinoma (HCC) and HIV.

HY-B0673R

Pirfenidone (Standard)	Inhibitor
Pirfenidone (Standard) is the analytical standard of Pirfenidone. This product is intended for research and analytical applications. Pirfenidone (AMR69) is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.

HY-P99697

Leronlimab	Antagonist	98.91%
Leronlimab (PRO 140) is a humanized IgG4 anti-CCR5 monoclonal antibody. Leronlimab inhibits CCR5-mediated HIV-1 viral and lung metastasis in mouse tumor models. Leronlimab can be used for the research of HIV nonalcoholic steatohepatitis (NASH) and cancer.

HY-156460

CMKLR1 antagonist 1	Antagonist	99.44%
CMKLR1 antagonist 1 (compound S-26d) is a potent and orally active chemokine-like receptor 1 (CMKLR1) antagonist, with a pIC₅₀ value of 7.44 in hCMKLR1-transfected CHO cells. CMKLR1 antagonist 1 can be used for psoriasis and metabolic diseases research.

HY-123763

MLN3126	Antagonist	98.02%
MLN3126 is an orally active and potent CCR9 antagonist. MLN3126 inhibits CCL25-induced calcium mobilization and chemotaxis of mouse primary thymocytes, wiht an IC₅₀ value of 6.3 nM for calcium influx.

HY-B0673S

Pirfenidone-d₅	Inhibitor	98.88%
Pirfenidone-d₅ is a deuterium labeled Pirfenidone. Pirfenidone is an antifibrotic agent that attenuates CCL2 and CCL12 production in fibrocyte cells. Pirfenidone has growth-inhibitory effect and reduces TGF-β2 protein levels in human glioma cell lines. Pirfenidone also has anti-inflammatory activities.

HY-148100A

Emapticap pegol sodium	Inhibitor
Emapticap pegol sodium is a inhibitor of pro-inflammatory chemokine C-C motif-ligand 2 (CCL2). Emapticap pegol sodium is a 40-nucleotide oligonucleotide aptamer, displays different Spiegelmers (L-RNA aptamer) isform in human (NOX-E36) and mouse (mNOX-E36).

HY-109511

AZD-1678	Antagonist	98.12%
AZD-1678 is a potent CCR4 receptor antagonist, with a pIC₅₀ of 8.6.

HY-162495

IDOR-1117-2520	Antagonist	99.94%
IDOR-1117-2520 is a potent and selective antagonist of CCR6. IDOR-1117-2520 antagonizes the CCL20-mediated calcium flow (IC₅₀ = 63 nM) and inhibits β-arrestin recruitment to human CCR6 (IC₅₀ = 30 nM) in cells expressing recombinant human CCR6. IDOR-1117-2520 can be used for research of autoimmune diseases.

HY-P990914

Denikitug		99.00%
HY-P990914 is an CCR8-targeting IgG1κ type chimeric antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991010

Nebokitug	Inhibitor	99.87%
HY-P991010 is an CCL24-targeting IgG1κ type human antibody, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).

Name
Email *

	Sorry, but the email address you supplied was invalid.